0001493152-24-007469.txt : 20240221 0001493152-24-007469.hdr.sgml : 20240221 20240221211027 ACCESSION NUMBER: 0001493152-24-007469 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240216 FILED AS OF DATE: 20240221 DATE AS OF CHANGE: 20240221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fletcher Kyle CENTRAL INDEX KEY: 0001937742 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38914 FILM NUMBER: 24662016 MAIL ADDRESS: STREET 1: CELULARITY INC. STREET 2: 170 PARK AVE. CITY: FLORHAM PARK STATE: NJ ZIP: 07932 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celularity Inc CENTRAL INDEX KEY: 0001752828 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 831702591 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 170 PARK AVE CITY: FLORHAM PARK STATE: NJ ZIP: 07932 BUSINESS PHONE: (908) 768-2170 MAIL ADDRESS: STREET 1: 170 PARK AVE CITY: FLORHAM PARK STATE: NJ ZIP: 07932 FORMER COMPANY: FORMER CONFORMED NAME: GX Acquisition Corp. DATE OF NAME CHANGE: 20180912 4 1 ownership.xml X0508 4 2024-02-16 0 0001752828 Celularity Inc CELU 0001937742 Fletcher Kyle C/O CELULARITY INC. 170 PARK AVENUE FLORHAM PARK NJ 07932 0 1 0 0 See Remarks 0 Class A Common Stock 2024-02-17 4 F 0 39571 0.434 D 217228 D Stock Option Grant (Right to Buy) 0.4340 2024-02-16 4 A 0 164171 0.00 A 2034-02-15 Class A Common Stock 164171 164171 D Represents shares withheld by the Issuer to satisfy the Reporting Person's tax obligations associated with the vesting and settlement of restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan") and does not represent a sale. Includes 209,891 shares underlying RSUs granted under the 2021 Plan. Each RSU represents the right to receive one share of the Issuer's Class A common stock subject to vesting. The option was granted pursuant to the 2021 Plan. The shares underlying such option will vest in equal quarterly installments during 2024 such that 25% of the option will vest on each of March 31, 2024, June 30, 2024, September 30, 2024 and December 31, 2024, subject to the Reporting Person's continuous service with the Issuer through each such date. Executive Vice President, General Counsel /s/ Kyle Fletcher 2024-02-21